11 / 14
Page 66
Notes:
conferenceseries
.com
Volume 8
Journal of Gastrointestinal & Digestive System
Gastro Meet 2018
August 06-07, 2018
August 06-07, 2018 Abu Dhabi, UAE
Gastroenterology and Digestive
Disorders
16
th
International Conference on
J Gastrointest Dig Syst 2018, Volume 8
DOI: 10.4172/2161-069X-C3-071
Volatile organic metabolites as novel, non-invasive diagnostic biomarkers of gastrointestinal disorders
Iftikhar Ahmed
East Sussex Hospitals NHS Foundation Trust, UK
T
he Diagnosis of gastrointestinal (GI) disorders requires extensive and often invasive investigations including colonoscopy
and histology and places a heavy burden, both on healthcare resources, because of the cost, and on the individual, in times
of disease-related disability and poor quality of life. Recently, there has been increasing interest in non-invasive biomarkers to
diagnose different GI diseases and to monitor the disease activity. There is growing scientific interest in the investigation of volatile
metabolites and numbers of studies have focused on the utilization of non-invasive biomarkers in the diagnosis of GI disease. The
development of sophisticated analytical techniques has enabled the study and interpretation of changes in the faecal and breath
volatile organic metabolites (VOMs) and its correlation with the pathophysiological mechanisms in the GI diseases. VOMs are
the chemicals that are the products and intermediates of metabolism and may be altered during the diseases process. Changes in
the signature of VOMs could potentially provide diagnostic information about health and disease. Multiple studies have reported
the differences in VOM profiles of healthy controls vs. patients with liver and other GI disorders. VOM profiles have been used
to segregate patients by disease activity and the type of disease. The correlation of VOMs with microbiota is interesting and
supports the hypothesis of gut microbial dysbiosis in the etiology of liver disease. This provides an important platform to explore
the role of dysbiosis in liver and other GI disorders pathogenesis and development of novel therapeutic targets. In future, further
understanding of faecal VOMs may lead to the development of a rapid and simple point of care diagnosis and monitoring of Liver.